Reviva Pharmaceuticals Holdings Inc (RVPH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.53-1.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RVPH
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||
| R&D Expenses | 6.7 | 11.7 | 22.9 | 31.4 | 22.9 | 4.9 | 0.3 | — |
| Operating Income | (13.5) | (20.2) | (30.8) | (39.5) | (28.2) | (10.1) | (2.4) | (0.2) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | 0.0 | — | — | — | 0.0 | 1.5 | — |
| Interest & Investment Income | 0.5 | 0.3 | 0.4 | 0.4 | — | — | 0.1 | 0.7 |
| Net Interest Expenses | — | — | — | — | — | — | 1.3 | — |
| Other Non-Operating Income / Expenses | 0.5 | 0.4 | 0.9 | 0.3 | (0.0) | 1.6 | (1.3) | — |
| EBT, Incl. Unusual Items | (13.0) | (19.8) | (29.9) | (39.2) | (28.2) | (8.5) | (3.8) | — |
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | ||||||||
| Net Income | (13.0) | (19.9) | (29.9) | (39.3) | (28.3) | (8.5) | (3.8) | 0.6 |
| Per Share | ||||||||
| Basic EPS | (0.99) | (5.48) | (0.90) | (1.65) | (1.45) | (0.58) | — | — |
| Basic Weighted Avg Shares | 13.2 | 3.6 | 33.1 | 23.8 | 19.5 | 14.8 | — | — |
| Supplemental | ||||||||
| EBIT | (13.5) | (20.2) | (30.8) | (39.5) | (28.2) | (10.1) | (2.4) | (0.2) |
| Effective Tax Rate | -0.1% | — | — | -0.0% | -0.1% | -0.1% | -0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.